Recently, Shanghai Weike Biotechnology Co., Ltd. announced the completion of tens of millions of angel rounds of financing, with the exclusive investment of BGI Win-Win. This round of financing will help Vico Bio to accelerate technology upgrades and team building, promote the expansion of testing services such as the cell gene therapy industry, the safety assessment of the gene editing and breeding industry, and the automation of laboratory platforms.
It is understood that Weike Bio was established in March 2021, and is committed to providing safety evaluation of vector insertion mutations for cell and gene therapy drugs. innovative enterprise. The technical team provided ISA testing for all gene therapy products that have been successfully marketed overseas.
Weike Bio is located in Lingang Life and Health City, Pujiang, Shanghai. It currently has an 800-square-meter clean laboratory that complies with GLP regulations, and the existing equipment assets of the laboratory exceed 8 million yuan. At the same time, Weike Bio has established a complete genomics and bioinformatics analysis platform, developed and verified NGS-based detection and analysis methods.
Relying on the plant microbial safety evaluation technology system jointly established with the Qingdao Plant Molecular Breeding Team of the Chinese Academy of Sciences, the Weike Bio Qingdao team aims to build a platform for the entire industry chain of plant molecular breeding, and build a service for the utilization and innovation of germplasm resources in my country. professional team.
Dr. Wu Ning, the founder of Weike Bio, said: “We are honored to receive the support of professional investment funds in this round. Although the gene therapy track is in full swing, showing broad development prospects, but safety issues such as gene insertion mutations always exist, and have always been It has attracted attention inside and outside the biopharmaceutical industry. Both LV vectors and AAV vectors have been widely used in the field of gene therapy and are considered to be very safe, but the risk of carcinogenicity caused by insertional mutations is still a safety that cannot be ignored in gene therapy products Question. What our company can do is to timely discover corresponding adverse events through long-term supervision, and escort the launch of cell and gene therapy drugs. For the treatment of rare diseases, if stem cells are used for gene editing, the tumorigenic risk induced Bigger. Vico Bio currently provides a full range of tests such as viral vector integration site analysis, gene editing quantitative off-target detection, vector copy number detection, and vector quality control, which can be detected early and intervened early to reduce the risk of mutation and tumorigenesis. At present Vico is cooperating with well-known domestic pharmaceutical companies and R&D institutions, hoping to further benefit patients.”
Ji Changtao, partner of Huada Win-Win Investment, said: “Hua Da Win-Win insists on R&D-driven investment, focusing on industry development trends and underlying logic. As technology, talents, and regulatory systems mature, cell gene therapy is the key to the future development of the biomedical industry. One of the important directions, we are firmly optimistic about the application of cell gene therapy in the fields of genetic diseases, rare diseases, tumors, nerves, infectious diseases, etc., and are also actively deploying the upstream delivery system, safety/toxicology research, equipment and consumables training of the cell gene therapy industry Ji et al. The core team of Weike Biotech originated from GENEWERK company founded by Professor Manfred Schmidt in Germany, and has helped many gene therapy drugs to pass the FDA and EMA approval; Weike Biotech has quickly built a complete set of cell and gene therapy after its establishment The safety evaluation technology system has been fully verified and applied in the fields of cell gene therapy and biological breeding. The excellent and pragmatic team, solid technology accumulation and leading layout have laid a good foundation for the rapid development of the company in the future.”
media reports
Arterial Network Arterial Network Yiou Pioneering State
related events
- ” Vike Bio” completed tens of millions of angel round financing, Huada Win-Win exclusive investment2022-12-20
- Bangyao Biotech completed hundreds of millions of yuan in round B financing2022-11-14
- Weiyou Gene completed the Pre-A round of financing of tens of millions of yuan2022-09-19
- Porton Biotech received hundreds of millions of RMB in Series B financing, led by China Merchants Health2022-08-22
- Shenyan Biology completed the B round of financing of 100 million yuan2022-06-21
This article is transferred from: https://readhub.cn/topic/8lTtso0UKmK
This site is only for collection, and the copyright belongs to the original author.